Overview
Generate:Biomedicines is a biotechnology company founded by Flagship Pioneering at the intersection of machine learning, biological engineering, and medicine. Founded in 2018 and based in Somerville, Massachusetts, with founders including Molly Gibson and Gevorg Grigoryan, the company is pioneering programmable biology, using generative AI to design proteins with desired properties rather than discovering them by trial and error.
Technology
The company's platform, often described as a generative drug-design engine, learns the patterns underlying protein structure and function to generate novel candidate therapeutics across modalities such as antibodies and peptides. This approach aims to compress discovery timelines and expand the universe of druggable targets by designing molecules to specification, then validating them in the lab and clinic.
Funding and Partnerships
Generate:Biomedicines has raised nearly $700M in equity financing, including a $370M Series B and a $273M Series C, with backers spanning Flagship Pioneering and strategic investors such as Samsung. It has formed major pharma collaborations, including a multi-target partnership with Novartis, positioning it among the leading generative-AI biotech companies advancing AI-designed medicines toward the clinic.